Cost-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in type 2 diabetes in Canada

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 23, Issue 2, 2016, Pages e151-e168

  Sabapathy, Suthakar ^a   Neslusan, Cheryl ^b   Yoong, Kim ^a   Teschemaker, Anna ^b   Johansen, Pierre ^c   Willis, Michael ^c  

^a Janssen Inc   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Canagliflozin; Cost effectiveness analysis; Sitagliptin; Third line therapy; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CANADA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; STATISTICAL MODEL;

AGED; BLOOD GLUCOSE; CANADA; CANAGLIFLOZIN; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS;

EID: 84991271189     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Statistics Canada. Diabetes, 2010. http://www.statcan.gc.ca/pub/82-625-x/2011001/article/11459-eng.htm. Accessed December 2, 2015.
2. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
3. Public Health Agency of Canada. Diabetes in Canada. Facts and figures from a public health perspective, 2011. http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/pdf/facts-figures-faits-chiffres-eng.pdf. Accessed March 2, 2016.
4. Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002;25(8):1303-7.
5. Canadian Diabetes Association. An economic tsunami: the costs of diabetes in Canada, December 2009. http://www.diabetes.ca/CDA/media/documents/publications-and-newsletters/advocacy-reports/economic-tsunami-cost-of-diabetes-in-canada-english.pdf. Accessed March 2, 2016.
6. Canadian Diabetes Association. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37(suppl 1):S1-212.
7. Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes 2013;37(2):82-9.
8. Canadian Agency for Drugs and Technologies in Health. CADTH Optimal Use Report. Second-line pharmacotherapy for type 2 diabetes– update. http://www.cadth.ca/media/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf.
9. Canadian Agency for Drugs and Technologies in Health. CADTH Optimal Use Report. Third-line pharmacotherapy for type 2 diabetes– update. http://www.cadth.ca/media/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf. Accessed March 2, 2016.
10. Morgan S, Smolina K, Mooney D, et al. The Canadian Rx Atlas. 3rd ed. UBC Centre for Health Services and Policy Research; 2013.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38(1):140-9.
12. Jabbour SA. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med 2014;126(1):111-7.
13. Canadian Drug Expert Committee. Common drug review: CDEC final recommendation, canagliflozin (Invokana, Janssen Inc.). http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0370_Invokana_Jan-19_15.pdf. Accessed March 2, 2016.
14. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015;1358:28-43.
15. Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin 2015;31(12):2219-31.
16. Weir MR. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med 2016;128(3):290-8.
17. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; doi:10.1056/NEJMoa1515920.
18. Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 2014;11(5):306-23.
19. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373(3):232-42.
20. Canadian Agency for Drugs and Technologies in Health. New drugs for type 2 diabetes: a therapeutic review update. https://www.cadth.ca/new-drugs-type-2-diabetes-therapeutic-review-update. Accessed February 25, 2016.
21. Palmer AJ; The Mount Hood 5 Modeling Group. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood Challenge meeting. Value Health 2013;16(4):670-85.
22. American Diabetes Association. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27(9):2262-5.
23. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed 2006. https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accessed March 2, 2016.
24. Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 2013;16(8):1007-21.
25. Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M. Update of the model validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Poster presented at: 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 21-25 2016;Washington, DC.
26. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the fourth Mount Hood Challenge meeting. Diabetes Care 2007;30(6):1638-46.
27. Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A. The Mt. Hood Challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000;50(suppl 3):S57-64.
28. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico. Value Health Regional Issues 2015;8:8-19.
29. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000;50(suppl 3):S15-46.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53.
31. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20(5):735-44.
32. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14(3):217-30.
33. Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 1. model construction, assumptions, and validation of health consequences. Am J Kidney Dis 2010;55(3):452-62.
34. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56(9):1925-33.
35. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43.
36. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290(23):3101-14.
37. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30(6):1109-19.
38. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126(1):7-17.
39. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013;36(9):2508-15.
40. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67(12):1267-82.
41. INVOKANA® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2014.
42. Janssen Research & Development. Integrated summary of efficacy. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. 2012.
43. Yamout HM, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014;40(1):64-74.
44. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51(3):408-16.
45. Riddle MC, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013;15(9):819-25.
46. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011;13(9):814-22.
47. Clarke PM, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med 2010;7(2):e1000236.
48. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28(11):1922-34.
49. Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 2003;49(11):76-84.
50. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25(3):1017-38.
51. O'Reilly D, Hopkins R, Blackhouse G, et al. Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario. Can J Diabetes 2007;31(3):205-14.
52. Regie de l'assurance maladie du Quebec. Liste des médicaments. Règlement concernant la liste des médicaments couverts par le régime général d'assurance médicaments. http://www.ramq.gouv.qc.ca/fr/publications/citoyens/publications-legales/Pages/liste-medicaments.aspx. Accessed March 2, 2016.
53. Ontario Ministry of Health and Long-term Care. Drugs funded by Ontario Drug Benefit (ODB) program. http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx. Accessed March 2, 2016.
54. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90.
55. Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ 2015;18(1):45-55.
56. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015;38(3):355-64.
57. National Institute for Health and Clinical Excellence. Obesity prevention: NICE guidelines [Clinical guideline 43]. http://www.nice.org.uk/guidance/CG43/. Accessed December 3, 2015.
58. Macran S. The relationship between body mass index and health-related quality of life (Discussion paper 190). http://www.york.ac.uk/che/pdf/DP190.pdf. Accessed March 2, 2016.
59. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117-28.
60. Kansal A, Zheng Y, Proskorovsky I, Krotneva S, Kandaswamy P, Ruffolo A. Modeling cardiovascular outcomes of treatment with empagliflozin in type 2 diabetes based on hard outcomes data. Poster presented at: 21st Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 21-25 2016; Washington, DC.
61. O'Reilly D, Burke N, Blackhouse G, Tsoi B, Campbell K, Jegathisawaran J. Review of the cost and health-related quality of life associated with diabetes and diabetes-related complications. 2012;TEMMP-D045-2012.REP.
62. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43(7):736-49.
63. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med 2006;23(10):1100-5.
64. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22(4):340-9.